High Eg5 expression predicts poor prognosis in breast cancer
Metrics: PDF 1158 views | HTML 1645 views | ?
Qin Jin1, Fang Huang1, Xudong Wang2, Huijun Zhu1, Yun Xian3, Jieying Li1, Shu Zhang1 and Qichao Ni4
1Department of Pathlogy, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
2Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
3Health Insurance Office, Nantong University, Nantong 226001, Jiangsu, China
4Department of General Surgery, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
Qichao Ni, email: firstname.lastname@example.org
Keywords: Eg5, BC, prognosis
Received: January 25, 2017 Accepted: April 12, 2017 Published: July 10, 2017
Eg5 is a motor protein belonging to the kinesin-5 family and has been suggested to exert important function in tumors. In this study, we determined the mRNA and protein expression levels of Eg5 in cancerous and non-cancerous breast tissue by quantitative real-time polymerase chain reaction (qRT-PCR) and tissue microarray immunohistochemistry analysis (TMA-IHC) respectively. The results of 20 fresh-frozen BC samples demonstrated that Eg5 mRNA levels were significantly higher in BC tissues compared with corresponding non-cancerous tissue (p = 0.0009). TMA-IHC analysis in 127 BC tissues revealed that Eg5 expression obviously correlated with clinicopathologial parameters, including tumor grade (p = 0.004), ER status (p = 0.030), Ki67 status (p = 0.005), molecular classification (p = 0.026), N stage (p = 0.015), and TNM stage (p = 0.001). Kaplan-Meier survival curve indicated that high Eg5 expression (p = 0.012), Ki67 status (p = 0.014) and TNM stage (p = 0.026) were independent factors to predict poor prognosis for patients with breast cancer. Our data suggest that Eg5 is not only overexpressed in BC, it may be also served as a potential prognostic marker.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.